BEAM Beam Therapeutics

The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020

The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020

Magazine honors company for second year in a row

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named one of the Top Places to Work in Massachusetts in the 13th annual employee-based survey project from The Boston Globe for the second year in a row. Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best: their employees. The survey measures employee opinions about their company’s direction, execution, connection, management, work, pay and benefits, and engagement.

The employers are placed into one of four groups: small, with 50 to 99 employees; medium, with 100 to 249 workers; large, with 250 to 999; and largest, with 1,000 or more. Beam was ranked as the top biotechnology company in the medium category and ranked 18 out of 55 in the category overall.

“Beam was undoubtedly a great place to work when we received this honor last year, and despite the unprecedented circumstances as a result of the global pandemic, it remains true in 2020,” said John Evans, chief executive officer of Beam Therapeutics. “COVID-19 has constantly challenged our teams to collaborate, innovate and stay connected in new ways. Our growth and progress over the course of 2020 speaks volumes to the exceptional values and commitment of every member of the Beam team.”

The rankings in Top Places to Work are based on confidential survey information collected by Energage, a Pennsylvania-based employee research and consulting firm specializing in employee engagement and retention, from over 80,000 employees at 285 Massachusetts organizations. The winners share a few key traits, including offering progressive benefits, giving their employees a voice, and encouraging them to have some fun while they’re at it.

"This was a particularly challenging year to be a great place to work, and the companies that made our list went above and beyond to keep their employees safe, engaged, and cared for," said Katie Johnston, the Globe's Top Places to Work editor. "From offering help with childcare to making the workplace more equitable to holding virtual talent shows, these employers showed that the best get better in crisis."

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization focused on its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit .

Contacts:

Media:

Dan Budwick

1AB

 

Investors:

Monique Allaire

THRUST Strategic Communications

 



EN
20/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Beam Therapeutics

 PRESS RELEASE

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Th...

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). “We are thrilled th...

 PRESS RELEASE

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Pr...

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Expanded Dose Exploration Underway in Part A and Enrollment Initiated in Part B; Data from Parts A and B of the Phase 1/2 Trial and Clinical Development Update Expected in Early 2026 Dosing Complete for 30 Sickle Cell Di...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch